# HeartSciences Inc.: financial statements, quarterly

HSCS · Nasdaq · CIK 1468492 · [Financials](/sectors/financials.md) · fiscal year ends Apr 30

Pages: [Overview](/companies/hscs.md) · [Financials](/companies/hscs/financials.md) · [Filings](/companies/hscs/filings.md) · [Insiders](/companies/hscs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hscs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [3.9](/filings/0000950170-24-136607.md) | [14.7](/filings/0000950170-25-038699.md) | [0.0 d](/filings/0000950170-25-098326.md) | not reported | not reported | [0.0](/filings/0001437749-26-008399.md) | [4.4 d](/filings/0001437749-26-024337.md) | [1.9](/filings/0001437749-26-030319.md) | [2.4](/filings/0001193125-25-319203.md) | [0.0](/filings/0001437749-26-008399.md) | [0.0 d](/filings/0001437749-26-024337.md) | [2.1](/filings/0001437749-26-030319.md) |
| Cost of revenue | $k | [1.5](/filings/0000950170-24-136607.md) | [4.6](/filings/0000950170-25-038699.md) | [0.0 d](/filings/0000950170-25-098326.md) | not reported | not reported | [0.0](/filings/0001437749-26-008399.md) | [1.9 d](/filings/0001437749-26-024337.md) | [0.8](/filings/0001437749-26-030319.md) | [1.0](/filings/0001193125-25-319203.md) | [0.0](/filings/0001437749-26-008399.md) | [0.0 d](/filings/0001437749-26-024337.md) | [0.8](/filings/0001437749-26-030319.md) |
| Gross profit | $k | [2.4](/filings/0000950170-24-136607.md) | [10.1](/filings/0000950170-25-038699.md) | [0.0 d](/filings/0000950170-25-098326.md) | not reported | not reported | [0.0](/filings/0001437749-26-008399.md) | [2.5 d](/filings/0001437749-26-024337.md) | [1.1](/filings/0001437749-26-030319.md) | [1.4](/filings/0001193125-25-319203.md) | [0.0](/filings/0001437749-26-008399.md) | [0.0 d](/filings/0001437749-26-024337.md) | [1.3](/filings/0001437749-26-030319.md) |
| Research and development | $k | [757](/filings/0000950170-24-136607.md) | [510](/filings/0000950170-25-038699.md) | [1,046 d](/filings/0000950170-25-098326.md) | [1,225](/filings/0001468492-25-000010.md) | [1,199](/filings/0001193125-25-319203.md) | [1,033](/filings/0001437749-26-008399.md) | [929 d](/filings/0001437749-26-024337.md) | [997](/filings/0001437749-26-030319.md) | [727](/filings/0001193125-25-319203.md) | [639](/filings/0001437749-26-008399.md) | [476 d](/filings/0001437749-26-024337.md) | [907](/filings/0001437749-26-030319.md) |
| Selling, general and administrative | $k | [815](/filings/0000950170-24-136607.md) | [1,026](/filings/0000950170-25-038699.md) | [834 d](/filings/0000950170-25-098326.md) | [851](/filings/0001468492-25-000010.md) | [786](/filings/0001193125-25-319203.md) | [1,338](/filings/0001437749-26-008399.md) | [994 d](/filings/0001437749-26-024337.md) | [878](/filings/0001437749-26-030319.md) | [1,348](/filings/0001193125-25-319203.md) | [1,290](/filings/0001437749-26-008399.md) | [2,060 d](/filings/0001437749-26-024337.md) | [2,034](/filings/0001437749-26-030319.md) |
| Operating income | $k | [(1,570)](/filings/0000950170-24-136607.md) | [(1,525)](/filings/0000950170-25-038699.md) | [(1,880) d](/filings/0000950170-25-098326.md) | [(2,076)](/filings/0001468492-25-000010.md) | [(1,985)](/filings/0001193125-25-319203.md) | [(2,371)](/filings/0001437749-26-008399.md) | [(1,920) d](/filings/0001437749-26-024337.md) | [(1,874)](/filings/0001437749-26-030319.md) | [(2,073)](/filings/0001193125-25-319203.md) | [(1,929)](/filings/0001437749-26-008399.md) | [(2,536) d](/filings/0001437749-26-024337.md) | [(2,939)](/filings/0001437749-26-030319.md) |
| Interest expense | $k | [178](/filings/0000950170-23-070381.md) | [118](/filings/0000950170-24-031457.md) | [20.9 d](/filings/0000950170-24-087271.md) | [22.5](/filings/0001468492-25-000010.md) | [118](/filings/0001193125-25-319203.md) | [179](/filings/0001437749-26-008399.md) | [181 d](/filings/0001437749-26-024337.md) | [184](/filings/0001437749-26-030319.md) | [280](/filings/0001193125-25-319203.md) | [61.5](/filings/0001437749-26-008399.md) | [228 d](/filings/0001437749-26-024337.md) | [235](/filings/0001437749-26-030319.md) |
| Net income | $k | [(1,748)](/filings/0000950170-24-136607.md) | [(1,644)](/filings/0000950170-25-038699.md) | [(1,846) d](/filings/0000950170-25-098326.md) | [(2,052)](/filings/0001468492-25-000010.md) | [(2,083)](/filings/0001193125-25-319203.md) | [(2,536)](/filings/0001437749-26-008399.md) | [(2,094) d](/filings/0001437749-26-024337.md) | [(2,055)](/filings/0001437749-26-030319.md) | [(2,351)](/filings/0001193125-25-319203.md) | [(1,985)](/filings/0001437749-26-008399.md) | [(2,751) d](/filings/0001437749-26-024337.md) | [(3,172)](/filings/0001437749-26-030319.md) |
| Diluted EPS | $ per share | [(15.92)](/filings/0000950170-24-136607.md) | [(3.01)](/filings/0000950170-25-038699.md) | not reported | [(2.64)](/filings/0001468492-25-000010.md) | [(2.27)](/filings/0001193125-25-319203.md) | [(2.57)](/filings/0000950170-25-038699.md) | not reported | [(1.58)](/filings/0001468492-25-000010.md) | [(0.85)](/filings/0001193125-25-319203.md) | not reported | not reported | not reported |
| Basic EPS | $ per share | [(15.92)](/filings/0000950170-24-136607.md) | [(3.01)](/filings/0000950170-25-038699.md) | not reported | [(2.64)](/filings/0001468492-25-000010.md) | [(2.27)](/filings/0001193125-25-319203.md) | [(2.57)](/filings/0001437749-26-008399.md) | not reported | [(1.58)](/filings/0001437749-26-030319.md) | [(0.85)](/filings/0001193125-25-319203.md) | [(0.63)](/filings/0001437749-26-008399.md) | not reported | [(0.86)](/filings/0001437749-26-030319.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | period not labelled (2025-12-31) | Q3 FY2026 (2026-01-31) | FY2026 (2026-04-30) | period not labelled (2026-06-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [5,808](/filings/0000950170-25-098326.md) | [4,340](/filings/0000950170-24-105914.md) | [4,052](/filings/0000950170-24-136607.md) | [2,597](/filings/0000950170-25-038699.md) | [1,100](/filings/0001437749-26-024337.md) | [2,792](/filings/0001468492-25-000010.md) | [1,951](/filings/0001193125-25-319203.md) | [1,098](/filings/0001437749-26-024337.md) | [3,397](/filings/0001437749-26-008399.md) | [1,657](/filings/0001437749-26-030319.md) | [1,657](/filings/0001437749-26-024337.md) | [29.9](/filings/0001437749-26-030319.md) |
| Current assets | $k | [7,354](/filings/0000950170-25-098326.md) | [6,075](/filings/0000950170-24-105914.md) | [5,689](/filings/0000950170-24-136607.md) | [3,629](/filings/0000950170-25-038699.md) | [2,171](/filings/0001437749-26-008399.md) | [4,417](/filings/0001468492-25-000010.md) | [3,793](/filings/0001193125-25-319203.md) | [2,171](/filings/0001437749-26-024337.md) | [5,099](/filings/0001437749-26-008399.md) | [2,583](/filings/0001437749-26-030319.md) | [2,583](/filings/0001437749-26-024337.md) | [812](/filings/0001437749-26-030319.md) |
| Total assets | $k | [9,503](/filings/0000950170-25-098326.md) | [8,191](/filings/0000950170-24-105914.md) | [7,777](/filings/0000950170-24-136607.md) | [5,704](/filings/0000950170-25-038699.md) | [4,223](/filings/0001437749-26-008399.md) | [6,437](/filings/0001468492-25-000010.md) | [5,996](/filings/0001193125-25-319203.md) | [4,223](/filings/0001437749-26-024337.md) | [7,555](/filings/0001437749-26-008399.md) | [5,263](/filings/0001437749-26-030319.md) | [5,263](/filings/0001437749-26-024337.md) | [3,737](/filings/0001437749-26-030319.md) |
| Current liabilities | $k | [1,752](/filings/0000950170-25-098326.md) | [1,352](/filings/0000950170-24-105914.md) | [3,303](/filings/0000950170-24-136607.md) | [3,571](/filings/0000950170-25-038699.md) | [3,703](/filings/0001437749-26-008399.md) | [3,015](/filings/0001468492-25-000010.md) | [1,566](/filings/0001193125-25-319203.md) | [3,703](/filings/0001437749-26-024337.md) | [4,269](/filings/0001437749-26-008399.md) | [4,861](/filings/0001437749-26-030319.md) | [4,861](/filings/0001437749-26-024337.md) | [5,633](/filings/0001437749-26-030319.md) |
| Total liabilities | $k | [2,186](/filings/0000950170-25-098326.md) | [2,257](/filings/0000950170-24-105914.md) | [3,761](/filings/0000950170-24-136607.md) | [3,917](/filings/0000950170-25-038699.md) | [4,018](/filings/0001437749-26-008399.md) | [3,296](/filings/0001468492-25-000010.md) | [1,814](/filings/0001193125-25-319203.md) | [4,018](/filings/0001437749-26-024337.md) | [4,902](/filings/0001437749-26-008399.md) | [5,037](/filings/0001437749-26-030319.md) | [5,037](/filings/0001437749-26-024337.md) | [5,770](/filings/0001437749-26-030319.md) |
| Shareholders' equity | $k | [7,317](/filings/0001437749-26-024337.md) | [5,934](/filings/0001193125-25-319203.md) | [4,017](/filings/0001437749-26-008399.md) | [1,787](/filings/0001437749-26-008399.md) | [205](/filings/0001437749-26-030319.md) | [3,141](/filings/0001437749-26-030319.md) | [4,182](/filings/0001437749-26-008399.md) | [205](/filings/0001437749-26-024337.md) | [2,652](/filings/0001437749-26-008399.md) | [226](/filings/0001437749-26-030319.md) | [226](/filings/0001437749-26-024337.md) | [(2,033)](/filings/0001437749-26-030319.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q4 FY2024 (2024-04-30) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(988) d](/filings/0000950170-24-136607.md) | [(2,101) d](/filings/0000950170-25-038699.md) | [(1,577) d](/filings/0000950170-25-098326.md) | [(2,019)](/filings/0001468492-25-000010.md) | [(2,184) d](/filings/0001193125-25-319203.md) | [(1,620) d](/filings/0001437749-26-008399.md) | [(1,591) d](/filings/0001437749-26-024337.md) | [(1,953)](/filings/0001437749-26-030319.md) | [(2,334) d](/filings/0001193125-25-319203.md) | [(1,463) d](/filings/0001437749-26-008399.md) | [(1,677) d](/filings/0001437749-26-024337.md) | [(1,319)](/filings/0001437749-26-030319.md) |
| Capital expenditure | $k | [2.0 d](/filings/0000950170-24-136607.md) | [8.8 d](/filings/0000950170-25-038699.md) | [48.8 d](/filings/0000950170-25-098326.md) | not reported | not reported | [0.0 d](/filings/0001437749-26-008399.md) | [0.0 d](/filings/0001437749-26-024337.md) | not reported | not reported | [(9.5) d](/filings/0001437749-26-008399.md) | [0.0 d](/filings/0001437749-26-024337.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-01-31) | Q1 FY2023 (2022-07-31) | Q2 FY2023 (2022-10-31) | Q3 FY2023 (2023-01-31) | Q1 FY2024 (2023-07-31) | Q2 FY2024 (2023-10-31) | Q3 FY2024 (2024-01-31) | Q1 FY2025 (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [3,324](/filings/0000950170-23-008432.md) | [5,645](/filings/0000950170-23-048168.md) | [8,210](/filings/0000950170-23-070381.md) | [8,241](/filings/0000950170-24-031457.md) | [103](/filings/0000950170-24-105914.md) | [110](/filings/0000950170-24-136607.md) | [547](/filings/0000950170-25-038699.md) | [778](/filings/0001468492-25-000010.md) | [917](/filings/0001193125-25-319203.md) | [986](/filings/0000950170-25-038699.md) | [1,304](/filings/0001468492-25-000010.md) | [2,780](/filings/0001193125-25-319203.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,800,172 at 2026-09-11, from the cover of the [10-Q filed 2026-09-14](/filings/0001437749-26-030319.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:40 ET. No prices; not investment advice.